Cancer Family
Mesothelial Neoplasm
CI-CAN-00000028Explore in graph →
Non-malignant108 active trials4 approved drugs13 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000028Explore in graph →
Clinical trials
521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02357147 | Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)(ARTEMIS) | terminated | Phase 2 | 124 | MorphotekINDUSTRY | 6 | Mar 17, 2020 | clinicaltrials |
| NCT00770120 | S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery | completed | Phase 2 | 61 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2020 |
| clinicaltrials |
| NCT02194231 | ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)(ATREUS) | completed | Phase 2 | 145 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT01624090 | Mithramycin for Lung, Esophagus, and Other Chest Cancers | terminated | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT00859469 | Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma | completed | Phase 2 | 29 | Columbia UniversityOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT00334594 | Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma | completed | Phase 2 | 153 | Swiss Cancer InstituteOTHER | 2 | May 15, 2019 | clinicaltrials |
| NCT02349958 | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy(HIPEC/IPHC) | unknown | Phase 2 | 200 | Bay Area Gynecology OncologyOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03175172 | Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) | terminated | Phase 2 | 10 | Aduro Biotech, Inc.INDUSTRY | 1 | Apr 4, 2019 | clinicaltrials |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | terminated | Phase 2 / Phase 3 | 545 | Boehringer IngelheimINDUSTRY | 27 | Mar 18, 2019 | clinicaltrials |
| NCT00484276 | Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma(NGR010) | completed | Phase 2 | 57 | AGC Biologics S.p.A.INDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01358084 | Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM(NGR019) | completed | Phase 2 | 137 | AGC Biologics S.p.A.INDUSTRY | 3 | Jan 15, 2019 | clinicaltrials |
| NCT02599194 | 18F-FSPG PET/CT for Cancer Patients on Therapy | completed | Phase 2 | 7 | Andrei IagaruOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT01592383 | Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma | completed | Phase 2 | 2 | University of ChicagoOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02397928 | Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) | completed | Phase 2 | 82 | NovoCure Ltd.INDUSTRY | 7 | Sep 25, 2018 | clinicaltrials |
| NCT00458913 | Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma | completed | Phase 2 | 82 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jul 12, 2018 | clinicaltrials |
| NCT00365053 | PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2018 | clinicaltrials |
| NCT01627795 | Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment | suspended | Phase 1 / Phase 2 | 17 | Oshadi Drug AdministrationINDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01160458 | Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2018 | clinicaltrials |
| NCT02758587 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | unknown | Phase 1 / Phase 2 | 59 | NHS Greater Glasgow and ClydeOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT00243074 | S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02497508 | Nivolumab in Patients With Recurrent Malignant Mesothelioma(NivoMes) | completed | Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 0 | Sep 14, 2017 | clinicaltrials |
| NCT01721018 | Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.(1716-12) | completed | Phase 1 / Phase 2 | 12 | Virttu Biologics LimitedINDUSTRY | 1 | Jun 9, 2017 | clinicaltrials |
| NCT01204203 | Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)(UAB0901) | completed | Phase 2 | 8 | University of Alabama at BirminghamOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00895648 | Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma | terminated | Phase 2 | 6 | University Health Network, TorontoOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT00604461 | Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM) | terminated | Phase 1 / Phase 2 | 13 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT01869023 | Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma | unknown | Phase 2 | 26 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01211275 | Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma(N08CPA) | completed | Phase 1 / Phase 2 | 32 | The Netherlands Cancer InstituteOTHER | 1 | Feb 28, 2017 | clinicaltrials |
| NCT01870609 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma(COMMAND) | terminated | Phase 2 | 344 | Verastem, Inc.INDUSTRY | 15 | Jan 30, 2017 | clinicaltrials |
| NCT00017186 | Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma | completed | Phase 2 | 69 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 7, 2016 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT02755675 | uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung | unknown | Phase 2 | 120 | Rigshospitalet, DenmarkOTHER | 1 | Nov 21, 2016 | clinicaltrials |
| NCT01861301 | Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT00597116 | An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma | terminated | Phase 2 | 25 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Oct 10, 2016 | clinicaltrials |
| NCT00165503 | Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate | terminated | Phase 2 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 9, 2016 | clinicaltrials |
| NCT00509041 | Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma | completed | Phase 2 | 46 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 11, 2016 | clinicaltrials |
| NCT00004183 | Capecitabine in Treating Patients With Malignant Mesothelioma | completed | Phase 2 | 27 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT00053885 | PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma | completed | Phase 2 | 47 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 1, 2016 | clinicaltrials |
| NCT00469196 | Tomotherapy Treatment for Mesothelioma | completed | Phase 2 | 18 | AHS Cancer Control AlbertaOTHER | 1 | Apr 6, 2016 | clinicaltrials |
| NCT00004547 | Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy | completed | Phase 2 | 188 | National Cancer Institute (NCI)NIH | 1 | Nov 18, 2015 | clinicaltrials |
| NCT02588131 | A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) | unknown | Phase 2 | 40 | Italian Network for Tumor Biotherapy FoundationOTHER | 1 | Oct 27, 2015 | clinicaltrials |
| NCT01769547 | A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy(DOVE-M) | terminated | Phase 2 | 12 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT02497053 | Four Versus Six Cycles of Pemetrexed/Platinum for MPM | unknown | Phase 2 | 70 | Ain Shams UniversityOTHER | 1 | Jul 14, 2015 | clinicaltrials |
| NCT01024946 | Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity | completed | Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT00027508 | Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma | terminated | Phase 2 | — | PharmaMarINDUSTRY | 1 | Feb 24, 2015 | clinicaltrials |
| NCT00459862 | Pazopanib in Treating Patients With Malignant Pleural Mesothelioma | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2015 | clinicaltrials |
| NCT00634205 | Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma | completed | Phase 2 | 45 | European Lung Cancer Working PartyOTHER | 2 | Feb 12, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Mar 17, 2020source: clinicaltrials